SAN FRANCISCO AND TOKYO, December 16, 2019: Morgan Lewis represented Yokogawa Electric Corp. in its acquisition of technology from BioStinger Inc. The nanopipette technology enables the injection of target substances, such as genes and drugs, into the target location of a specific cell and the extraction of individual intracellular materials.
BioStinger is a corporation that was founded by a professor who is a leading authority in single-cell analysis and other academics. Tokyo-based Yokogawa engages in broad-ranging business activities in the areas of measurement, control, information, and serves various industries, including pharmaceuticals, through its global network.
Partners Nancy Yamaguchi, Karen Abesamis, and Rahul Kapoor led the Morgan Lewis team advising Yokogawa, while partners Ken Nunnenkamp and Giovanna Cinelli led on Committee on Foreign Investment in the United States (CFIUS) matters.